Prognostic value of single nucleotide polymorphisms of candidate genes associated with inflammation in early stage breast cancer

被引:0
作者
James L. Murray
Patricia Thompson
Suk Young Yoo
Kim-Anh Do
Mala Pande
Renke Zhou
Yanhong Liu
Aysegul A. Sahin
Melissa L. Bondy
Abenaa M. Brewster
机构
[1] The University of Texas MD Anderson Cancer Center,
[2] The Arizona Cancer Center,undefined
[3] Baylor College of Medicine,undefined
来源
Breast Cancer Research and Treatment | 2013年 / 138卷
关键词
Gene polymorphisms; Inflammation; Breast cancer;
D O I
暂无
中图分类号
学科分类号
摘要
To examine the role of germline genetic variations in inflammatory pathways as modifiers of time to recurrence (TTR) in patients with early stage breast cancer (BC), DNA from 997 early stage BC patients was genotyped for 53 tagging single nucleotide polymorphisms (SNPs) in 12 genes involved in inflammation. SNPs were analyzed separately for Caucasians versus African-Americans and Hispanics. Cox proportional hazards models were used to evaluate the association between SNPs in the inflammatory genes and TTR, adjusted for clinical and pathologic covariates. In univariable analyses of Caucasian women, the homozygous genotype of 12 SNPs, including 6 NFKB1 SNPs, 4 IL4 SNPs, and 2 IL13 SNPs, were significantly associated with a decrease in TTR compared with the heterozygous and/or corresponding homozygous genotype (P < 0.05). The significant NFKB1 and IL4 SNPs were in an area of high linkage disequilibrium (D′ > 0.8). After adjusting for stage, age, and treatment, carriage of the homozygous genotypes for NFKB1 rs230532 and IL13rs1800925 were independently associated with a shorter TTR (P = 0.001 and P = 0.034, respectively). In African-American and Hispanic patients, expression of NFKB1 rs3774932, TNFrs1799964, and IL4rs3024543 SNPs were associated with a shorter TTR in univariable model. Only NFKB1 rs3774932 (P = 0.02) and IL4Rrs3024543 (P = 0.03) had independent prognostic value in the multivariable model These data support the existence of host genetic susceptibility as a component in recurrence risk mediated by pro-inflammatory and immune factors, and suggest the potential for drugs which modify immune responses and inflammatory genes to improve prognosis in early stage BC.
引用
收藏
页码:917 / 924
页数:7
相关论文
共 245 条
  • [1] Jemal A(2009)Cancer statistics, 2009 CA Cancer J Clin 59 225-249
  • [2] Siegel R(2008)Residual risk of breast cancer recurrence 5 years after adjuvant therapy J Natl Cancer Inst 100 1179-1183
  • [3] Ward E(2004)Prognostic and predictive factors in early-stage breast cancer Oncologist 9 606-616
  • [4] Hao Y(1989)Prognostic value of histologic grade nuclear components of Scarff–Bloom–Richardson (SBR). An improved score modification based on a multivariate analysis of 1,262 invasive ductal breast carcinomas Cancer 64 1914-1921
  • [5] Xu J(2003)Estrogen receptors and distinct patterns of breast cancer relapse Breast Cancer Res Treat 78 105-118
  • [6] Thun MJ(2001)HER2 as a prognostic factor in breast cancer Oncology 61 67-72
  • [7] Brewster AM(2001)Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci USA 98 10869-10874
  • [8] Hortobagyi GN(2000)Molecular portraits of human breast tumours Nature 406 747-752
  • [9] Broglio KR(2004)Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds PLoS Biol 2 E7-4323
  • [10] Kau SW(2007)An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer Genome Biol 8 R157-444